Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Macular Degeneration × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Brain Neoplasms 1731 Glioblastoma 1620 Glioma 1022 Central Nervous System Neoplasms 549 Astrocytoma 538 Neuroblastoma 503 Gliosarcoma 428 Oligodendroglioma 335 Neoplasms 286 Breast Neoplasms 254 Medulloblastoma 240 Carcinoma, Non-Small-Cell Lung 206 Recurrence 178 Sarcoma 168 Meningioma 164 Melanoma 164 Ependymoma 164 Neoplasm Metastasis 163 Lung Neoplasms 138 Lymphoma 122 Osteosarcoma 117 Meningeal Carcinomatosis 114 Neurofibromatosis 1 107 Wilms Tumor 103 Ovarian Neoplasms 98 Precursor Cell Lymphoblastic Leukemia-Lymphoma 96 Diffuse Intrinsic Pontine Glioma 96 Rhabdomyosarcoma 93 Lymphoma, Non-Hodgkin 92 Burkitt Lymphoma 83

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡